Document is current

Article History

Received: 16 September 2024

Revised: 28 December 2024

Accepted: 21 January 2025

First Online: 6 March 2025

Compliance with ethical standards

:

: The scientific guarantor of this publication is L.P.V.

: The following authors of this manuscript declare relationships with the following companies: S.R.: research grants and/or consulting fees from AbbVie, Eli Lilly, Galapagos, Janssen, MSD, Novartis, Pfizer, UCB, Sanofi; F.v.G.: grant and/or consulting fees from, Abbvie, ASAS, BMS, Galapagos, Janssen, Lilly, Novartis, Pfizer, and UCB; P.C.: consulting fees from AbbVie, Amgen, Biogen, Celltrion, Galapagos, Janssen, Lilly, MSD, Novartis, Pfizer and UCB (less than US$10 000 each), investigator for Abbvie, Janssen, Lilly, MSD, Novartis and Pfizer. D.v.d.H.: consulting fees AbbVie, Alfasigma, ArgenX, BMS, Elly-Lilly, Grey-Wolf Therapeutics, Janssen, Novartis, Pfizer, Takeda, and UCB Pharma. Associate editor Annals Rheumatic Diseases, editorial board member Journal of Rheumatology and RMD Open. Advisor Assessment Axial Spondyloarthritis international Society and director of Imaging Rheumatology bv. M.R.: ASAS consultant, ISS research grant. The other authors of this manuscript declare no relationships with any companies, whose products or services may be related to the subject matter of the article.

: S.R. and L.P.V. have significant statistical expertise. No complex statistical methods were necessary for this paper.

: Written informed consent was obtained from all subjects (patients) in this study.

: Institutional Review Board approval was obtained (Comité de Protection des Personnes Ile de France III).

: The study subjects or cohorts have not already been previously reported.

: